Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials
Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials
To allow continuation of axitinib (AG 013736) treatment to patients experiencing clinical
 benefit in a closing axitinib trial
This is a roll over study aimed to provide continued access to axitinib (monotherapy or
 combination, according to treatment received in prior axitinib study) to patients who have
 documented stable, or responding disease, or received clinical benefit (as defined by
 protocol) at the time of the prior study closure.
Inclusion Criteria:

 -  Patients who were assigned to an axitinib (AG-013736) containing treatment arm in a
 previous clinical trial

 -  Patients who were receiving axitinib (AG-013736) tablets at the time their previous
 trial ended

 -  Patients who have stable (SD) or responding disease (PR or CR) documented by the
 appropriate radiological, clinical, or laboratory assessments within 12 weeks before
 enrollment (Note: response criteria from the previous axitinib (AG-013736) protocol
 should be used to determine stable or responding disease).

 -  Patients who have progressive disease (PD) but have experienced "clinical benefit" as
 defined in the study protocol

 Exclusion Criteria:

 -  Patients may not participate in this trial if the conditions for continuing treatment
 in the previous axitinib (AG-013736) protocol are not met